SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/279469"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/279469" > Biganzoli Laura > Quality of life und...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004287naa a2200661 4500
001oai:gup.ub.gu.se/279469
003SwePub
008240910s2019 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:140920600
0247 a https://gup.ub.gu.se/publication/2794692 URI
0247 a https://doi.org/10.1038/s41416-019-0435-42 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1409206002 URI
040 a (SwePub)gud (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Ribi, Karin4 aut
2451 0a Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
264 c 2019-04-10
264 1b Springer Science and Business Media LLC,c 2019
520 a In the phase III SOLE trial, the extended use of intermittent versus continuous letrozole for 5 years did not improve disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Intermittent therapy with 3-month breaks may be beneficial for patients' quality of life (QoL).In the SOLE QoL sub-study, 956 patients completed the Breast Cancer Prevention Trial (BCPT) symptom and further QoL scales up to 24 months after randomisation. Differences in change of QoL from baseline between the two administration schedules were tested at 12 and 24 months using repeated measures mixed-models. The primary outcome was change in hot flushes at 12 months.There was no difference in hot flushes at 12 months between the two schedules, but patients receiving intermittent letrozole reported significantly more improvement at 24 months. They also indicated less worsening in vaginal problems, musculoskeletal pain, sleep disturbance, physical well-being and mood at 12 months. Overall, 25-30% of patients reported a clinically relevant worsening in key symptoms and global QoL.Less symptom worsening was observed during the first year of extended treatment with the intermittent administration. For women experiencing an increased symptom burden of extended adjuvant endocrine therapy, an intermittent administration is a safe alternative.Clinical trial information: NCT00651456.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Luo, Weixiu4 aut
7001 a Colleoni, Marco4 aut
7001 a Karlsson, Per,d 1963u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology4 aut0 (Swepub:gu)xkperd
7001 a Chirgwin, Jacquie4 aut
7001 a Aebi, Stefan4 aut
7001 a Jerusalem, Guy4 aut
7001 a Neven, Patrick4 aut
7001 a Di Lauro, Vincenzo4 aut
7001 a Gomez, Henry L4 aut
7001 a Ruhstaller, Thomas4 aut
7001 a Abdi, Ehtesham4 aut
7001 a Biganzoli, Laura4 aut
7001 a Müller, Bettina4 aut
7001 a Barbeaux, Annelore4 aut
7001 a Graas, Marie-Pascale4 aut
7001 a Rabaglio, Manuela4 aut
7001 a Francis, Prudence A4 aut
7001 a Foukakis, Theodorosu Karolinska Institutet4 aut
7001 a Pagani, Olivia4 aut
7001 a Graiff, Claudio4 aut
7001 a Vorobiof, Daniel4 aut
7001 a Maibach, Rudolf4 aut
7001 a Di Leo, Angelo4 aut
7001 a Gelber, Richard D4 aut
7001 a Goldhirsch, Aron4 aut
7001 a Coates, Alan S4 aut
7001 a Regan, Meredith M4 aut
7001 a Bernhard, Jürg4 aut
7102 a Göteborgs universitetb Institutionen för kliniska vetenskaper, Avdelningen för onkologi4 org
7730 t British journal of cancerd : Springer Science and Business Media LLCg 120, s. 959-967q 120<959-967x 1532-1827x 0007-0920
8564 u https://www.nature.com/articles/s41416-019-0435-4.pdf
8564 8u https://gup.ub.gu.se/publication/279469
8564 8u https://doi.org/10.1038/s41416-019-0435-4
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:140920600

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy